RxDoctor Payments Data

Victoria Lawrence-Gilbert, APRN

Family · Vanceburg, KYNPI 1699059345

Payments from drug & device makers

$1,271in general payments, 2019–2025

Across 68 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$238
  • GSK$222
  • Biohaven Pharmaceutical Holding Company Ltd.$109
  • AbbVie$104
  • Abbott$98
  • AstraZeneca$93
  • plus $407 from 13 others

What the payments were for

  • Food & beverage$1,271100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,271 in reported general payments places this provider in the 70th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$3,535
Medicare patients
41
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate78$104,114
JardianceEmpagliflozin46$65,051
OzempicSemaglutide44$44,964
FarxigaDapagliflozin Propanediol35$42,434
TrulicityDulaglutide24$29,098
EliquisApixaban16$27,365
Lantus SolostarInsulin Glargine,hum.Rec.Anlog123$19,238
TradjentaLinagliptin13$18,148
XareltoRivaroxaban11$17,254
LinzessLinaclotide16$12,593
MounjaroTirzepatide12$12,089
Bydureon BciseExenatide Microspheres13$10,268
VascepaIcosapent Ethyl14$5,639
Humalog Kwikpen U-100Insulin Lispro36$5,610
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp19$5,593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$45$104,11478 claims
Boehringer IngelheimJardiance, Tradjenta$15$83,19959 claims
Novo NordiskOzempic$65$44,96444 claims
AstraZenecaFarxiga$93$42,43435 claims
Lilly USA, LLCTrulicity, Mounjaro$13$41,18736 claims
AbbVieLinzess, Synthroid$104$13,32231 claims
GSKShingrix$222$4,67523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,374 family providers in Kentucky.

Other family in Vanceburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →